

-5-

Serial No. 09/868,131

1. (Currently Amended) A method of activating a serum and glucocorticoid-induced protein kinase (SGK) comprising:
contacting a SGK comprising SEQ ID NO:45 or SEQ ID NO:48 or both with a compound wherein the SGK is phosphorylated by the compound and wherein the compound ~~is a~~ has PDK1 or a ~~variant, fragment, or fusion thereof, or a fusion of said variant or fragment or a preparation having~~ PDK2 activity.
- 2.-6. Canceled
7. (Previously Presented) A method according to claim 1 wherein the SGK is phosphorylated on the residue equivalent to Thr256 of full-length human SGK1.
8. (Previously Presented) A method according to claim 1 wherein the SGK is phosphorylated on the residue equivalent to Ser422 of full-length human SGK1.
9. (Original) A method according to claim 8 wherein the SGK is further phosphorylated on the residue equivalent to Thr256 of full-length human SGK1.
- 10.-43. Canceled
44. (Previously Presented) The method according to claims 1, 7, or 8, wherein the SGK is SGK1, SGK2 α , SGK2 β or SGK3.
- 45.-50. Cancelled
51. (Currently Amended) The method according to claims 1, 7, or 8 wherein the compound ~~PDK1 or a variant, fragment or fusion thereof or a fusion of said variant or fragment~~ phosphorylates a polypeptide which comprises SEQ ID NO:48.

C:\Clients\002\00160\01252006amendment.wpd

-6-

Serial No. 09/868,131

52. (Currently Amended) The method according to claim 1, 7, or 8 wherein the ~~preparation compound~~ having PDK2 activity phosphorylates a polypeptide which comprises SEQ ID NO:45.

53. (Previously Presented) The method according to claim 1, wherein the SGK is capable of phosphorylating a polypeptide comprising SEQ ID NO:49.

54. (Currently Amended) The method according to claim 53, wherein the SGK ~~has at least 65% identity with a~~ comprises ~~full length human SGK1,~~ SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:8.

55. (New) The method according to claim 1, wherein the compound is in a preparation.